Theralase TechnologiesTLTFF +1.22%46 Days Inventory is 657.00 as of Mar. 2026, which is 55% above its 10-year median of 423.68. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 93% on this metric.
The historical rank and industry rank for Theralase Technologies's Days Inventory or its related term are showing as below:
TLTFF'
s Days Inventory Range Over the Past 10 Years
Min: 320.74 Med: 423.68 Max: 620.15
Current: 610.44
During the past 13 years, Theralase Technologies's highest Days Inventory was 620.15. The lowest was 320.74. And the median was 423.68.
TLTFF's Days Inventory is ranked worse than 93% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs TLTFF: 610.44
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Theralase Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.14.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Theralase Technologies's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 3.71.
Theralase Technologies (OTCPK:TLTFF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Theralase Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Theralase Technologies's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Theralase Technologies Days Inventory Related Terms
Theralase Technologies Days Inventory Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Days Inventory of 657.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Theralase Technologies and its competitors. This is 55% above median its historical median of 423.68. Over the past decade, Theralase Technologies' Days Inventory has ranged from 320.74 to 620.15. According to the industry distribution chart, Theralase Technologies ranks #731 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 93%.
Is Theralase Technologies' Days Inventory too high?
Theralase Technologies' current Days Inventory of 657.00 is 55% above median its 10-year median of 423.68. Over the past 10 years, this metric has ranged from a low of 320.74 to a high of 620.15. The Medical Devices & Instruments industry median Days Inventory is 179.86. Theralase Technologies' value of 657.00 is 265.3% above this industry median. Based on the distribution chart, Theralase Technologies ranks #731 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #731 out of 786 companies for Days Inventory. This places Theralase Technologies in the lower half of its industry. The industry median Days Inventory is 179.86. Theralase Technologies' value of 657.00 is 265.3% above this benchmark. Historically, Theralase Technologies' own Days Inventory has ranged from 320.74 to 620.15 over the past decade. While the company's 10-year median is 423.68 vs. the industry median of 179.86, Theralase Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Days Inventory of 657.00 is 265.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Days Inventory is 657.00, which is 55% above median its own 10-year median of 423.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Days Inventory is 657.00, which is 55% above median its 10-year median of 423.68 and 265.3% above the Medical Devices & Instruments industry median of 179.86. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Days Inventory is 657.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
Days Inventory: 657.00 (55% above median its 10-year median of 423.68)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 265.3% above the Medical Devices & Instruments median (#731 of 786)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
